Assessing Patient Participation Burden Based on Protocol Design Characteristics.

patient participation burden protocol design complexity protocol design optimization study volunteer burden

Journal

Therapeutic innovation & regulatory science
ISSN: 2168-4804
Titre abrégé: Ther Innov Regul Sci
Pays: Switzerland
ID NLM: 101597411

Informations de publication

Date de publication:
05 2020
Historique:
received: 03 05 2019
accepted: 11 07 2019
entrez: 10 12 2020
pubmed: 11 12 2020
medline: 25 6 2021
Statut: ppublish

Résumé

Although a number of studies have quantitatively measured investigative site burden to administer increasingly complex protocol designs, robust scholarly research has not been performed to quantify the burden that patients face as participants in clinical trials. This paper presents the results of a cross-sectional pilot study conducted by the Tufts Center for the Study of Drug Development and ZS Associates among nearly 600 patients via an online survey conducted between February and March 2019. Respondents rated the perceived burden of 60 commonly administered protocol procedures. The association and relationship between overall patient burden-derived from aggregating mean perceived burden ratings for individual procedures-and performance (eg, screen failure and retention rates, clinical trial cycle times) for a cross-sectional sample of 137 individual protocols was assessed. Descriptive statistics, significance tests, and univariate analyses were performed. Strong positive, statistically significant associations were observed between a composite measure of patient burden and protocol-specific design and performance measures, most notably study visits above the tolerable mean and the study conduct duration from first patient first visit to last patient last visit. The study results suggest a new and viable approach to optimize protocol design and improve patient engagement.

Sections du résumé

BACKGROUND
Although a number of studies have quantitatively measured investigative site burden to administer increasingly complex protocol designs, robust scholarly research has not been performed to quantify the burden that patients face as participants in clinical trials.
METHODS
This paper presents the results of a cross-sectional pilot study conducted by the Tufts Center for the Study of Drug Development and ZS Associates among nearly 600 patients via an online survey conducted between February and March 2019. Respondents rated the perceived burden of 60 commonly administered protocol procedures. The association and relationship between overall patient burden-derived from aggregating mean perceived burden ratings for individual procedures-and performance (eg, screen failure and retention rates, clinical trial cycle times) for a cross-sectional sample of 137 individual protocols was assessed. Descriptive statistics, significance tests, and univariate analyses were performed.
RESULTS
Strong positive, statistically significant associations were observed between a composite measure of patient burden and protocol-specific design and performance measures, most notably study visits above the tolerable mean and the study conduct duration from first patient first visit to last patient last visit.
CONCLUSIONS
The study results suggest a new and viable approach to optimize protocol design and improve patient engagement.

Identifiants

pubmed: 33301141
doi: 10.1007/s43441-019-00092-4
pii: 10.1007/s43441-019-00092-4
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

598-604

Auteurs

Kenneth Getz (K)

The Center for the Study of Drug Development, Tufts University School of Medicine, 75 Kneeland Street, Boston, 021111, MA, USA. kenneth.getz@tufts.edu.

Venkat Sethuraman (V)

ZS Associates, Boston, MA, USA.

Jessica Rine (J)

ZS Associates, Boston, MA, USA.

Yaritza Peña (Y)

The Center for the Study of Drug Development, Tufts University School of Medicine, 75 Kneeland Street, Boston, 021111, MA, USA.

Sharma Ramanathan (S)

ZS Associates, Boston, MA, USA.

Stella Stergiopoulos (S)

The Center for the Study of Drug Development, Tufts University School of Medicine, 75 Kneeland Street, Boston, 021111, MA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH